Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Lung Neoplasms 19Ovarian Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Fallopian Tube Neoplasms 13Colorectal Neoplasms 11Pancreatic Neoplasms 9Carcinoma, Hepatocellular 8Melanoma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large B-Cell, Diffuse 5Prostatic Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Sezary Syndrome 3Sarcoma 3Rectal Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Glioblastoma 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3

Interventions

Gemcitabine 82Cisplatin 52Oxaliplatin 36lenvatinib 24durvalumab 22Capecitabine 22Fluorouracil 20Leucovorin 15tislelizumab 11pembrolizumab 10apatinib 10Radiotherapy 10Albumin-Bound Paclitaxel 10Radiofrequency Ablation 9Magnetic Resonance Spectroscopy 9Irinotecan 9Floxuridine 9Liver Transplantation 8Drug Therapy 8Cholangiopancreatography, Endoscopic Retrograde 8130-nm albumin-bound paclitaxel 8Taxes 7Platinum 7Photochemotherapy 7Panitumumab 7Biopsy 71,2-diaminocyclohexaneplatinum II citrate 7tremelimumab 6pemigatinib 6camrelizumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Cholangiocarcinoma × Disulfides × Clear all
NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

Jonsson Comprehensive Cancer Center

Phase 1 Not yet recruiting
46 enrolled
Gastrointestinal

Pancreatic Neoplasms, Cholangiocarcinoma

NCT06058663 2026-05-13

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Recruiting
16 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Mayo Clinic

Phase 1/2 Recruiting
85 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡